Topics

Glioblastoma | Treatment | Antiepileptic drugs | Larotrectinib

Home > Publications > Topics > Glioblastoma > Treatment > Antiepileptic drugs > Larotrectinib

Thavaneswaran S, Sim HW, Grady J, Espinoza D, Huang ML, Lin F, McGrath M, Desai J, Charakidis M, Brown M, Kansara M, Simes J, Thomas D.
A phase II trial of larotrectinib in tumors with NTRK fusions or extremes of NTRK mRNA overexpression identified by comprehensive genomic profiling.
Oncologist. 2024 Dec 25:oyae339. doi: 10.1093/oncolo/oyae339. PMID: 39720993. Interventional study. ˍ